Anapol Schwartz Announces New Mylan Generic Keppra Website

The Pennsylvania personal injury law firm of Anapol Weiss is proud to announce the debut of its new Mylan Generic Keppra website,

To help consumers and patients become more familiar with the potential risks of Keppra and Mylan generic Keppra, Anapol Weiss’s new website addresses epilepsy, types of seizures, seizure statistics, generic Keppra side effects, generic Keppra, Levetiracetam (LVT), Topamax, Anti Epilepsy Drugs (AEDs), as well as the differences between generic and name brand drugs. The website also serves as a helpful resource for patients who have experienced serious side effects after their pharmacy switched them from the brand name to a generic without the patient’s or neurologist’s approval, or even notification.

As one of the leading manufacturers of generic drugs in the world, Mylan received final approval by the Food and Drug Administration (FDA) in 2009 to manufacture a generic substitute for the anti-seizure medication, Keppra, developed by UCB Pharmaceuticals Inc. and marketed to epilepsy patients. However, some generic Keppra users have experienced breakthrough seizures and also several other serious side effects despite being seizure free for years and not experiencing any side effects on brand name Keppra.

Those interested in learning more about the plausible dangers of Keppra and Mylan generic Keppra are encouraged to visit Anapol Weiss’s new Mylan Generic Keppra website. Patients who have experienced sporadic increases in seizures and other severe side effects after switching from Keppra to a generic substitute are not helpless. Individuals who have been harmed by pharmaceutical products have valid legal rights and deserve to fully understand them in addition to knowing possible options for obtaining compensation from negligent drug manufacturers, pharmacy employees, or physicians.

For more information regarding Keppra and Mylan generic Keppra, please visit or contact the skilled Mylan generic Keppra lawyers at Anapol Weiss for a free consultation by calling 866-735-2792.

Read the related report about the anti seizure drug Topamax which increases risk of newborn cleft palate.

Contact Information